← All trials
NCT05133791
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 23, 2021
- Primary completion
- Jan 1, 2023
- Completion date
- Jan 1, 2023
- First posted
- Nov 24, 2021
- Last posted
- Nov 24, 2021
- Enrollment
- 16
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of GroningenLead sponsor
- University of GroningenReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.